Plain-English translation of NCT06089590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large safety study following 6,000 patients in France who are taking newer medications for inflammatory bowel disease (IBD), including treatments like JAK inhibitors, anti-IL23p19 drugs, and S1P modulators. Researchers want to understand how often serious side effects—such as cancer, serious infections, or blood clots—occur with these newer treatments. By tracking patients' health over time, the study will help doctors understand which treatments are safest and most effective.
These newer medications are promising treatments for IBD, but doctors need more information about their long-term safety in real-world use. This study will help identify any serious risks and help your doctor choose the best treatment for you.
You likely qualify if…
You likely don't qualify if…
You will continue taking your regular IBD medication while the study team collects information about your health and safety. Every three months, you'll answer questions online about how you're feeling and any symptoms you experience. The study coordinators may contact you by phone or email to check in. Your doctors will also share information about your disease status, any complications, and any side effects you experience. The study will follow you for at least 3.5 years.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France
Sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Collaborators
Sanoia
Enrollment target
~6,000 participants
Started
January 2024
Primary completion
March 2031
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marie Coisnon
Hôpital Saint Antoine - APHP
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.